Every month, the editors from the portfolio of scientific journals published by the AACR select one “must read” article from each issue, which we summarize here. The May edition includes a description of a deep learning-based algorithm to examine the tumor microenvironment in lung cancer for risk prediction, an examination of the role that the protein myocilin plays in cancer-associated cachexia, along with results from two clinical trials, among other studies.
A study shows that a more tolerable, dose-adjusted chemotherapy regimen can effectively treat a rare lymphoma, and more news of the week from Cancer Today.
The days are getting longer and warmer, and visions of beach trips, cookouts, and picnics occupy our minds. While this year’s summer will likely look different due to the ongoing COVID-19 pandemic, months of staying inside may make the desire to head outside even stronger.
The FDA approved a combination of an immunotherapy and a therapeutic that can stop tumors from growing blood vessels for certain patients with liver cancer.
Signaling pathways that regulate cellular proliferation are commonly mutated in cancer cells, leading to unrestrained cellular division and tumor growth. Therefore, insight into the regulation of these signaling pathways is critical to the development of novel therapeutics. Mutations in the RAS...
Metastatic prostate cancer incidence rose after changes to prostate cancer screening guidelines.
The FDA has expanded the use of the PARP-targeted therapeutic olaparib to include the treatment of certain patients with metastatic prostate cancer. The U.S. Food and Drug Administration (FDA) has expanded the use of...
The FDA has approved a new molecularly targeted therapeutic for treating certain patients who have advanced gastrointestinal stromal tumors.
Findings from a recent study suggest that patients may experience a greater occurrence of infections in the years preceding a cancer diagnosis.
The FDA has expanded the use of a molecularly targeted therapeutic to include the treatment of certain patients with prostate cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More